Analysts Set Abbott Laboratories (NYSE:ABT) Target Price at $118.61

Shares of Abbott Laboratories (NYSE:ABT) have been assigned a consensus rating of “Moderate Buy” from the twenty-six brokerages that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $118.6087.

Several analysts have commented on the company. Citigroup increased their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday. TD Cowen reaffirmed a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a report on Friday. Leerink Partners dropped their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Oppenheimer decreased their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. raised their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday.

Insiders Place Their Bets

In related news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by company insiders.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently bought and sold shares of the stock. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.0%

Abbott Laboratories stock opened at $101.72 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The business’s fifty day simple moving average is $90.28 and its two-hundred day simple moving average is $101.84. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a market capitalization of $177.18 billion, a price-to-earnings ratio of 32.92, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company’s revenue was up 13.0% on a year-over-year basis. During the same period last year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.